Pharmaceuticals

Fighting Diseases

A swimmer is swimming underwater in a pool.
Latest News
July 17, 2024
Not intended for U.S. and UK Media
Darolutamide meets primary endpoint in Phase III ARANOTE trial in men with metastatic hormone-sensitive prostate cancer
July 11, 2024
Not intended for UK Media
AskBio receives FDA Fast Track and MHRA Innovation Passport designations for AB-1005 investigational GDNF gene therapy for Parkinson’s disease
June 21, 2024
Not intended for U.S. and UK Media - Joint press release of Charité and Bayer
Berlin Center for Gene and Cell Therapies kicked off in Berlin
June 17, 2024
Crop Science Innovation Update 2024:
Bayer to deliver ten blockbusters in ten years
May 28, 2024
World Seed Congress 2024:
Bayer advances genome-editing initiatives for nutrition enhanced vegetables
May 16, 2024
Not intended for UK Media – Late-breaking data from pivotal Phase III studies OASIS 1 and 2 to be presented at 2024 ACOG Annual Meeting:
Elinzanetant significantly reduces frequency and severity of moderate to severe hot flashes associated with menopause
May 14, 2024
Bayer Group:
First-quarter performance as expected
April 26, 2024
CEO Bill Anderson at the Annual Stockholders’ Meeting:
“Restore trust and get Bayer on track for better performance”
April 23, 2024
Bayer Aims to Launch First Bioinsecticide for Arable Crops
March 20, 2024
Not intended for UK Media
Bayer Pharmaceuticals streamlines Leadership Team for next phase of growth
March 19, 2024
Not intended for UK Media
Positive topline results from Phase III long-term study OASIS 3 support submissions for marketing authorization for Bayer’s elinzanetant
March 05, 2024
Financial News Conference:
Bayer aims to enhance performance and regain strategic flexibility by 2026 – adjusted guidance for 2023 achieved
February 29, 2024
Heiko Schipper to leave the company on April 30, 2024
Julio Triana appointed to Board of Management of Bayer AG and President of the Consumer Health Division
February 29, 2024
Elections at the Annual Stockholders' Meeting on April 26, 2024:
Bayer aims to further extend expertise in Supervisory Board
February 26, 2024
Not intended for UK Media
Bayer receives U.S. FDA Breakthrough Therapy designation for BAY 2927088 for non-small cell lung cancer harboring HER2 activating mutations
February 19, 2024
Bayer plans to amend its dividend policy to reduce debt
January 24, 2024
Not intended for U.S. and UK Media
Application for regulatory approval of Aflibercept 8 mg accepted in China
January 18, 2024
Not intended for U.S. and UK Media
New Eylea™ 8 mg approved in Japan
January 17, 2024
Board of Management and employee representatives agree on future direction
Bayer aims to sustainably improve performance with new organization
January 08, 2024
Not intended for U.S. and UK Media
New Eylea™ 8 mg approved in EU
January 08, 2024
Not intended for UK Media
Bayer’s elinzanetant meets all primary and key secondary endpoints in pivotal OASIS 1 and 2 Phase III studies
January 04, 2024
Not intended for UK Media
AskBio Phase Ib trial of AB-1005 gene therapy in patients with Parkinson’s disease meets primary endpoint
November 19, 2023
Not intended for U.S. and UK Media
OCEANIC-AF study stopped early due to lack of efficacy
November 08, 2023
Bayer Group:
Third quarter below prior year as expected – Group outlook confirmed
October 16, 2023
6th International Rice Congress in Manila, Philippines:
Bayer introduces agricultural system for direct-seeded rice with potential to reduce greenhouse gas emissions and water use by up to 40 percent
October 05, 2023
Not intended for UK Media
Bayer to partner with Twist Bioscience to accelerate drug discovery
September 21, 2023
More than 70% of farmers have already seen large impacts of climate change on their farm, new global research across 8 countries reveals
September 18, 2023
Not intended for UK Media
Vividion Therapeutics starts Phase I clinical trial in advanced solid tumors with KEAP1 activator
August 29, 2023
Gene Editing: Pairwise and Bayer start new five-year multi-million Dollar collaboration to further advance short-stature corn
August 28, 2023
Not intended for UK Media
BlueRock’s Phase I study with bemdaneprocel in patients with Parkinson’s disease meets primary endpoint
August 21, 2023
Heike Prinz appointed to Board of Management of Bayer AG
August 10, 2023
Not intended for U.S. and UK Media – Two-year topline results from the pivotal study PULSAR:
Aflibercept 8 mg first to achieve sustained vision gains with more than 70% of patients extended to intervals between 16 and 24 weeks in wet age-related macular degeneration at two years
August 08, 2023
Bayer Group:
Second quarter impacted by declines in glyphosate business
July 24, 2023
Bayer lowers full-year outlook
June 29, 2023
Not intended for U.S. and UK Media
Aflibercept 8 mg in diabetic macular edema first to achieve sustained vision gains with up to 83% of patients extended to 16-24 weeks at two years
June 22, 2023
Not intended for U.S. and UK Media
Bayer to start Phase III study with finerenone in adults with chronic kidney disease and type 1 diabetes
June 20, 2023
Crop Science Innovation Summit 2023:
Bayer sees more than doubling of accessible markets and potential to shape regenerative agriculture on more than 400 million acres
May 23, 2023
NOT FOR DISTRIBUTION IN THE UNITED STATES OF AMERICA, AUSTRALIA, CANADA, SOUTH AFRICA OR JAPAN
Bayer issues new senior bonds with a volume of 3 billion euros
May 16, 2023
Not intended for UK Media
Bayer receives U.S. FDA Fast Track Designation for asundexian atrial fibrillation program
May 11, 2023
Bayer Group business performance in the first quarter of 2023:
Slow start to the year as expected
May 10, 2023
Not intended for U.S. and UK Media
Bayer initiates phase III study to investigate aflibercept 8 mg in retinal vein occlusion
April 28, 2023
CEO Werner Baumann at the Annual Stockholders’ Meeting:
“Bayer has excellent prospects for the future”
April 05, 2023
Bayer to invest a total of 60 million euros in its Ukrainian seed production site
April 03, 2023
Internationally renowned experts form independent Bayer Bioethics Council
Bayer establishes Bioethics Council
March 21, 2023
UN 2023 Water Conference:
Bayer pledges to help tackle global water crisis with new water strategy
March 20, 2023
Not intended for U.S. and UK Media
Nubeqa™ (darolutamide) approved for additional prostate cancer indication in China
March 01, 2023
Not intended for U.S. and UK Media
Nubeqa™ (darolutamide) receives EU approval for additional indication in prostate cancer
March 01, 2023
Not intended for U.S. and UK Media
Bayer submits aflibercept 8 mg for marketing authorization in Japan
February 28, 2023
Fiscal 2022
Bayer: Significant growth in sales and earnings
February 27, 2023
Not intended for U.S. and UK Media
Nubeqa™ approved for additional indication in Japan